<?xml version="1.0" encoding="utf-8"?>
<!DOCTYPE trials [
<!ELEMENT trials (trial+)>

<!ELEMENT trial (main,contacts,countries,criteria,health_condition_code,health_condition_keyword,intervention_code,
          intervention_keyword,primary_outcome,secondary_outcome,secondary_sponsor,secondary_ids,source_support,ethics_reviews)>

<!ELEMENT main (trial_id,utrn?,reg_name,date_registration,primary_sponsor,public_title,acronym?,scientific_title,scientific_acronym?,
          date_enrolment,type_enrolment,target_size,recruitment_status,url?,study_type,study_design,phase,hc_freetext?,i_freetext?,results_actual_enrolment,results_date_completed,results_url_link,results_summary,           results_date_posted,results_date_first_publication,results_baseline_char,results_participant_flow,results_adverse_events,results_outcome_measures,results_url_protocol,results_IPD_plan, results_IPD_description)>
<!ELEMENT trial_id (#PCDATA)>
<!ELEMENT utrn (#PCDATA)>
<!ELEMENT reg_name (#PCDATA)>
<!ELEMENT date_registration (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT primary_sponsor (#PCDATA)>
<!ELEMENT public_title (#PCDATA)>
<!ELEMENT acronym (#PCDATA)>
<!ELEMENT scientific_title (#PCDATA)>
<!ELEMENT scientific_acronym (#PCDATA)>
<!ELEMENT date_enrolment (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT type_enrolment (#PCDATA)>
<!ELEMENT target_size (#PCDATA)>
<!ELEMENT recruitment_status (#PCDATA)><!-- Pending,Recruiting,Suspended,Complete,Other -->
<!ELEMENT url (#PCDATA)>
<!ELEMENT study_type (#PCDATA)><!-- interventional,observational -->
<!ELEMENT study_design (#PCDATA)>
<!ELEMENT phase (#PCDATA)>
<!ELEMENT hc_freetext (#PCDATA)>
<!ELEMENT i_freetext (#PCDATA)>
<!ELEMENT results_actual_enrolment (#PCDATA)>
<!ELEMENT results_date_completed (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT results_url_link (#PCDATA)>
<!ELEMENT results_summary (#PCDATA)>
<!ELEMENT results_date_posted (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT results_date_first_publication (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT results_baseline_char (#PCDATA)>
<!ELEMENT results_participant_flow (#PCDATA)>
<!ELEMENT results_adverse_events (#PCDATA)>
<!ELEMENT results_outcome_measures (#PCDATA)>
<!ELEMENT results_url_protocol (#PCDATA)>
<!ELEMENT results_IPD_plan (#PCDATA)>
<!ELEMENT results_IPD_description (#PCDATA)>


<!ELEMENT contacts (contact+)>
<!ELEMENT contact (type,firstname,middlename,lastname,address,city,country1,zip,telephone,email,affiliation)>
<!ELEMENT type (#PCDATA)><!-- Public,Scientific -->
<!ELEMENT firstname (#PCDATA)>
<!ELEMENT middlename (#PCDATA)>
<!ELEMENT lastname (#PCDATA)>
<!ELEMENT address (#PCDATA)>
<!ELEMENT city (#PCDATA)>
<!ELEMENT country1 (#PCDATA)>
<!ELEMENT zip (#PCDATA)>
<!ELEMENT telephone (#PCDATA)>
<!ELEMENT email (#PCDATA)>
<!ELEMENT affiliation (#PCDATA)>

<!ELEMENT countries (country2+)>
<!ELEMENT country2 (#PCDATA)>

<!ELEMENT criteria (inclusion_criteria,agemin,agemax,gender,exclusion_criteria)>
<!ELEMENT inclusion_criteria (#PCDATA)>
<!ELEMENT agemin (#PCDATA)>
<!ELEMENT agemax (#PCDATA)>
<!ELEMENT gender (#PCDATA)>
<!ELEMENT exclusion_criteria (#PCDATA)>

<!ELEMENT health_condition_code (hc_code+)>
<!ELEMENT hc_code (#PCDATA)>

<!ELEMENT health_condition_keyword (hc_keyword+)>
<!ELEMENT hc_keyword (#PCDATA)>

<!ELEMENT intervention_code (i_code+)>
<!ELEMENT i_code (#PCDATA)>

<!ELEMENT intervention_keyword (i_keyword+)>
<!ELEMENT i_keyword (#PCDATA)>

<!ELEMENT primary_outcome (prim_outcome+)>
<!ELEMENT prim_outcome (#PCDATA)>

<!ELEMENT secondary_outcome (sec_outcome+)>
<!ELEMENT sec_outcome (#PCDATA)>

<!ELEMENT secondary_sponsor (sponsor_name+)>
<!ELEMENT sponsor_name (#PCDATA)>

<!ELEMENT secondary_ids (secondary_id+)>
<!ELEMENT secondary_id (sec_id,issuing_authority)>
<!ELEMENT sec_id (#PCDATA)>
<!ELEMENT issuing_authority (#PCDATA)>

<!ELEMENT source_support (source_name+)>
<!ELEMENT source_name (#PCDATA)>

<!ELEMENT ethics_reviews (ethics_review+)>
<!ELEMENT ethics_review (status,approval_date,contact_name,contact_address,contact_phone,contact_email)>
<!ELEMENT status (#PCDATA)><!-- Not approved,Approved,NA -->
<!ELEMENT approval_date (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT contact_name (#PCDATA)>
<!ELEMENT contact_address (#PCDATA)>
<!ELEMENT contact_phone (#PCDATA)>
<!ELEMENT contact_email (#PCDATA)>
]>
<trials>
  <trial>
    <main>
      <trial_id>IRCT20220203053922N1</trial_id>
      <utrn></utrn>
      <reg_name>IRCT</reg_name>
      <date_registration>2022-03-19</date_registration>
      <primary_sponsor>Esfahan University of Medical Sciences</primary_sponsor>
      <public_title>Comparative study of the effect of hypnotherapy and Monstrogol capsule on primary dysmenorrhea in girls living in dormitories of Isfahan University of Medical Science in 2022</public_title>
      <acronym></acronym>
      <scientific_title>Comparative study of the effect of hypnotherapy and Monstrogol capsule on primary dysmenorrhea</scientific_title>
      <scientific_acronym></scientific_acronym>
      <date_enrolment>2022-04-04</date_enrolment>
      <type_enrolment>anticipated</type_enrolment>
      <target_size>72</target_size>
      <recruitment_status>Complete</recruitment_status>
      <url>https://irct.ir/trial/61977</url>
      <study_type>interventional</study_type>
      <study_design>Randomization: Randomized, Blinding: Double blinded, Placebo: Not used, Assignment: Parallel, Purpose: Treatment, Randomization description: In this research, sample selection and random assignment in two groups using Minimization software will be used; In this way, the list of people is entered into the software by coding and people are randomly selected by the software, and are placed in two groups of test and control, Blinding description: This research will be a double-blind clinical trial (because the analyzer and the questioner will be unaware of which group the people are in) and the collection of information and random allocation of samples using Minimization software, so this study, two Group (test and control group) is three-stage and multivariate. The questioner is not aware of the grouping of individuals when recording information and results, and the analyzer is not aware of the grouping of individuals when analyzing data, and individuals are examined by specific codes.</study_design>
      <phase>3</phase>
      <hc_freetext>Primary dysmenorrhea.</hc_freetext>
      <i_freetext>Intervention 1: Intervention group: Hypnotherapy. Hypnotherapy will be performed in three sessions of 20 minutes for the experimental group individually.In the first session, hypnotherapy is introduced as a safe and uncomplicated medical treatment and also indoctrination test is performed. At the end of the first session, a light ecstasy and simple relaxation are given to the subjects.In the second session, various techniques are used to enter the trance, and following the involuntary closing of the eyes, inductions related to muscle relaxation and deepening techniques will be performed, and analgesia will begin. In the hypnosis phase, conditioning is done and they learn how to be able to anesthetize their desired areas. In the third session, trance practice and self-hypnotherapy will be performed and more deepening techniques will be used and people will be conditioned to fall into ecstasy when hearing dysmenorrhea by listening to the researcher's instincts and immediately anesthetize their desired points. After these steps, with the onset of dysmenorrhea, the subjects will be able to enter the trance and begin analgesia by listening to the researcher's hypnotherapy. Intervention 2: Control group: Menstrog capsule. Monstrogol (dry extract of saffron stigma, anise and celery) is a herbal capsule that has the effect of reducing menstrual pain and has an effect on smooth muscle contraction and has anti-inflammatory properties. This capsule contains 1/4 mg of dry extract powder of saffron stigma, 1/60 mg of dry extract powder of anise fruit and 1/16 mg of dry extract powder of celery. The amount of drug is 2.8-2.2 microliters of total essential oil and 3.1-1 microliters of anethole in each capsule. People in the control group of Monstrogol drug produced by Gol Daroo Company take one capsule every 8 hours for 3 days.</i_freetext>
      <results_actual_enrolment></results_actual_enrolment>
      <results_date_completed></results_date_completed>
      <results_url_link></results_url_link>
      <results_summary></results_summary>
      <results_date_posted></results_date_posted>
      <results_date_first_publication></results_date_first_publication>
      <results_baseline_char></results_baseline_char>
      <results_participant_flow></results_participant_flow>
      <results_adverse_events></results_adverse_events>
      <results_outcome_measures></results_outcome_measures>
      <results_url_protocol></results_url_protocol>
      <results_IPD_plan>No - There is not a plan to make this available</results_IPD_plan>
      <results_IPD_description>Justification or reason for not sharing IPD is Confidentiality of information of the subjects</results_IPD_description>
    </main>
    <contacts>
      <contact>
        <type>public</type>
        <firstname>Dr. Mahboobeh Valiani</firstname>
        <middlename></middlename>
        <lastname></lastname>
        <address>Hezar Jerib st.</address>
        <city>Isfahan</city>
        <country1>Iran (Islamic Republic of)</country1>
        <zip>81746-73461</zip>
        <telephone>+98 31 3668 0048</telephone>
        <email>Mahboobehvaliani@gmail.com</email>
        <affiliation>Esfahan University of Medical Sciences</affiliation>
      </contact>
      <contact>
        <type>scientific</type>
        <firstname>Dr. Mehdi Fathi</firstname>
        <middlename></middlename>
        <lastname></lastname>
        <address>Danesh va Salamat Town, between Shahid Javan and Al-Shahidi Squares, Shahid Fakoori Boulevard</address>
        <city>Mashhad</city>
        <country1>Iran (Islamic Republic of)</country1>
        <zip>13944-91388</zip>
        <telephone>+98 51 3841 2081</telephone>
        <email>mandala_110@yahoo.com</email>
        <affiliation>Mashhad University of Medical Sciences</affiliation>
      </contact>
    </contacts>
    <countries>
      <country2>Iran (Islamic Republic of)</country2>
    </countries>
    <criteria>
      <inclusion_criteria>Conscious consent to participate in research
Single students living in dormitories
Suffering age 25-18 years
Having regular menstrual periods
Having primary dysmenorrhea for at least two consecutive previous periods
No application of complementary medicine methods during the last two months
Painful menstruation in most menstrual cycles with a pain score of at least 4 out of 10 according to the Visual Analogue Scale (VAS) during two periodic periods
Hypnosis of people</inclusion_criteria>
      <agemin>no limit</agemin>
      <agemax>no limit</agemax>
      <gender>Female</gender>
      <exclusion_criteria>Any known disease of the genital tract
Secondary dysmenorrhea
History of abdominal or pelvic surgery
Endometriosis
Tobacco use (cigarettes, hookah and drugs), alcohol
Speech, hearing, and mental problems
Heart, kidney, respiratory, diabetes, asthma, hypothyroidism or hyperthyroidism, epilepsy and other patients in need of medication
Sudden weight loss
Special diet (vegetarian)
Do professional exercise and intense physical exercises
Use of herbs, traditional and complementary medicine during the last two months
Psychological problems and diseases requiring medication (bipolar disorder, psychosis, major depression, obsession, borderline disorders, dependent personality disorder, schizoid personality disorder, paranoid personality disorder) based on self-reported research units
Having coagulation disorders and taking anticoagulants
Existence of depression in the individual based on the score obtained from the DASS21 questionnaire</exclusion_criteria>
    </criteria>
    <health_condition_code>
      <hc_code></hc_code>
    </health_condition_code>
    <health_condition_keyword>
      <hc_keyword></hc_keyword>
    </health_condition_keyword>
    <intervention_code>
      <i_code>Treatment - Other</i_code>
      <i_code>Treatment - Drugs</i_code>
    </intervention_code>
    <intervention_keyword>
      <i_keyword>Intervention group: Hypnotherapy. Hypnotherapy will be performed in three sessions of 20 minutes for the experimental group individually.In the first session, hypnotherapy is introduced as a safe and uncomplicated medical treatment and also indoctrination test is performed. At the end of the first session, a light ecstasy and simple relaxation are given to the subjects.In the second session, various techniques are used to enter the trance, and following the involuntary closing of the eyes, inductions related to muscle relaxation and deepening techniques will be performed, and analgesia will begin. In the hypnosis phase, conditioning is done and they learn how to be able to anesthetize their desired areas. In the third session, trance practice and self-hypnotherapy will be performed and more deepening techniques will be used and people will be conditioned to fall into ecstasy when hearing dysmenorrhea by listening to the researcher's instincts and immediately anesthetize their desired points. After these steps, with the onset of dysmenorrhea, the subjects will be able to enter the trance and begin analgesia by listening to the researcher's hypnotherapy.</i_keyword>
      <i_keyword>Control group: Menstrog capsule. Monstrogol (dry extract of saffron stigma, anise and celery) is a herbal capsule that has the effect of reducing menstrual pain and has an effect on smooth muscle contraction and has anti-inflammatory properties. This capsule contains 1/4 mg of dry extract powder of saffron stigma, 1/60 mg of dry extract powder of anise fruit and 1/16 mg of dry extract powder of celery. The amount of drug is 2.8-2.2 microliters of total essential oil and 3.1-1 microliters of anethole in each capsule. People in the control group of Monstrogol drug produced by Gol Daroo Company take one capsule every 8 hours for 3 days.</i_keyword>
    </intervention_keyword>
    <primary_outcome>
      <prim_outcome>Pain score. Timepoint: Before. Immediately and two months after the intervention. Method of measurement: Pain ruler.</prim_outcome>
      <prim_outcome>Number of pain days. Timepoint: Before. Immediately and two months after the intervention. Method of measurement: Asking the patient.</prim_outcome>
      <prim_outcome>Bleeding volume. Timepoint: Before. Immediately and two months after the intervention. Method of measurement: PBLAC chart.</prim_outcome>
    </primary_outcome>
    <secondary_outcome>
      <sec_outcome></sec_outcome>
    </secondary_outcome>
    <secondary_sponsor>
      <sponsor_name></sponsor_name>
    </secondary_sponsor>
    <secondary_ids>
      <secondary_id>
        <sec_id></sec_id>
        <issuing_authority></issuing_authority>
      </secondary_id>
    </secondary_ids>
    <source_support>
      <source_name>Esfahan University of Medical Sciences</source_name>
    </source_support>
    <ethics_reviews>
      <ethics_review>
        <status>Approved</status>
        <approval_date>2022-01-31</approval_date>
        <contact_name>Ethics committee of Isfahan University of Medical Sciences</contact_name>
        <contact_address>22 plack, No. 4 West, Narvan st, Shahed blvd Shahin Shahr Isfehan Iran (Islamic Republic of)</contact_address>
        <contact_phone></contact_phone>
        <contact_email></contact_email>
      </ethics_review>
    </ethics_reviews>
  </trial>
</trials>
